Publication at Faculty of Medicine in Hradec Králové |
2017
Abstract
Dyspnoea is a serious symptom requiring causal and/or palliative management in a variety of acute and chronic clinical conditions. It has been shown that inhaled furosemide (IAF) has the potential to be a new effective approach to dyspnoea management in a number of indications.
This route of administration exerts significant bronchodilatation, relieves dyspnoea by suppressing the afferentation to the central nervous system and has a minimum diuretic effect. The author summarizes our current knowledge about the use of IAF in bronchial asthma, chronic obstructive pulmonary disease, heart failure and in the palliative treatment of dyspnoea, and presents a case report series in this article.